KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Resmed (RMD) Cash from Restructuring (2023)

Resmed's Cash from Restructuring history spans 1 years, with the latest figure at $9.2 million for Q2 2023.

For Q2 2023, Cash from Restructuring changed N/A year-over-year to $9.2 million; the TTM value through Mar 2025 reached $9.2 million, changed N/A, while the annual FY2024 figure was $33.2 million, 262.2% up from the prior year.
Cash from Restructuring reached $9.2 million in Q2 2023 per RMD's latest filing.
In the past five years, Cash from Restructuring ranged from a high of $9.2 million in Q2 2023 to a low of $9.2 million in Q2 2023.